Navigation Links
U-M study shows updated rotavirus vaccine not linked to increase in bowel obstruction
Date:1/4/2012

The rotovirus vaccine was pulled from the marketplace in 1999 after being associated with painful gastrointestinal complications, however, the updated rotavirus vaccines do not appear to increase the occurrence of these potentially fatal side effects, according to a new study by child health experts at C.S. Mott Children's Hospital.

The two updated versions of the vaccine,re-introduced in 2006 and 2008, prevent infection by rotavirus, which causes vomiting, abdominal pain, severe diarrhea and frequently requires hospitalization for young infants and children. Rotavirus was once the leading cause of gastrointestinal illness among children in the U.S.

The new study, published in this week's Archives of Pediatric Adolescent Medicine, shows the re-introduction of the vaccine has not caused an increase in a severe bowel obstruction called intussusception, the side effect that led to the original vaccine's withdrawal.

"We always need to carefully weigh the risks and benefits of childhood vaccines. Fortunately, our results suggest that rotavirus vaccines have not increased the rate of intussusception in the U.S.," says pediatrician Joe Zickafoose, M.D., M.S., a research fellow with the Child Health Evaluation and Research Unit.

Recent international studies have shown that, among vaccinated infants, the two latest rotavirus vaccines may be associated with a small increase in cases of intussusception.

However, the re-introduction of rotavirus vaccines in the United States did not appear to increase the rate of hospitalizations for intussusception.

More than 70 percent of infants in the U.S. have been vaccinated against rotavirus. The re-introduction of rotavirus vaccines is credited with reducing the number of diarrhea-related outpatient visits, emergency department visits, and hospitalizations among children.

Data used in the study came from the Healthcare Cost and Utlization Project's Kids' Inpatient Database, which is a sample of 80 percent of national pediatric discharges. The study focused on children younger than 1-year-old based on previous data which showed the most cases on intussusception occur within weeks of the vaccine being administered at ages 2-months, 4-months and 6-months old.

The investigators examined data trends from the decade prior to vaccine re-introduction, 1997-2006, and then made comparisons to data after vaccine re-introduction.

When comparing data, investigators expected to see 36 intussusception-related hospitalizations per 100,000 children under 1-year-old by 2009.

Despite the re-introduction of the vaccines, there were only 33.3 hospitalizations per 100,000 children in 2009, making it very unlikely that the vaccines led to additional cases.

The latest versions of the rotavirus vaccine were licensed following studies in over 70,000 children, which showed no increased risk for intussusception among those vaccinated. However, there has been lingering concern that a small amount of risk may have been missed in these studies.

"We hope that our study provides information that will continue to reassure parents that the benefits of rotavirus vaccine outweigh the risks," says Zickafoose, lead author of the study.


'/>"/>
Contact: Lauren McLeod
lemcleod@med.umich.edu
734-764-2220
University of Michigan Health System
Source:Eurekalert

Related medicine news :

1. U.S. Heart Attack Patients Readmitted Most Often: Study
2. Nap-deprived tots may be missing out on more than sleep, says University of Colorado-led study
3. Womens Sexual Satisfaction Often Rises With Age: Study
4. BINGO! game helps researchers study perception deficits
5. Genetic predisposition to disease common in 2 supercentenarians: New study
6. Study Looks at Deep Brain Stimulation in Bipolar Patients
7. Study finds another potential risk factor for developing dementia and Alzheimers disease in women
8. Study evaluates effects of marijuana ingredients on brain functioning during visual stimuli
9. Gene Mutations Linked to Thyroid Cancer Risk: Study
10. U.S. Blacks More Likely to Die of Colon Cancer Than Whites: Study
11. Multiple Sclerosis May Cause Changes in Thalamus: Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2017)... ... 23, 2017 , ... “Life Under Blankets”: an entrancing story about one ... Under Blankets” is the creation of published author, Kimberly Mitchell, who earned her bachelor’s ... went on to pursue a master’s degree in education in the field of curriculum ...
(Date:1/23/2017)... , ... January 23, 2017 , ... Valentine’s Day is a time when many people ... ones. For those who may be looking for the ideal present, Atlanta-based Perimeter Plastic ... get an additional $25 free. Or, spend $200 and get $50 free. , “A ...
(Date:1/22/2017)... FL (PRWEB) , ... January 22, 2017 , ... Zifam ... customers across the world, recently met with big-name retail buyers at the January ECRM ... evidence of efficacy and uses the utmost safety standards in all of its creations ...
(Date:1/22/2017)... TX (PRWEB) , ... January 22, 2017 , ... ... provide slow results. Often the results of a simple test will take days to ... Any Lab Test Now offers customers direct access to their lab tests, bypassing the ...
(Date:1/21/2017)... Raton, FL (PRWEB) , ... January 21, 2017 , ... ... Germany, announced it is bringing its product to the United States as part of ... over the last 25 years, Alcovit aims to reduce the productions of nasty toxins ...
Breaking Medicine News(10 mins):
(Date:1/23/2017)... 2017 A new Transparency Market Research report ... valued at US$0.53 bn in 2013 and is predicted to touch ... between 2014 and 2022. The title of the report is "Non-invasive ... Growth, Trends and Forecast 2014 - 2022." ... Non-invasive prenatal testing (NIPT), also referred to ...
(Date:1/23/2017)... SAN DIEGO , 23 janvier 2017  ResMed ... Winter Haven , Floride) ont annoncé aujourd,hui qu,ils se ... les litiges existants entre les parties. BMC et 3B ... de paiements de droits à ResMed, et ResMed effectuera ... à 3B pour clore le litige de Floride entre ...
(Date:1/23/2017)... Jan 23, 2017 NeuroVive Pharmaceutical AB ... signed a preclinical collaboration agreement with the Children,s Hospital of ... Falk , M.D., a US key opinion leader in the ... ... evaluate compounds from NeuroVive,s research program, NVP015, in certain experimental ...
Breaking Medicine Technology: